Beta Pharma
| Founded | 1996 |
|---|---|
| Headquarters |
5 Vaughn Drive Princeton, NJ, US |
| Website | www.betapharma.com |
Beta Pharma, Inc. is an emerging American pharmaceutical company based out of Princeton, NJ, dedicated to the discovery, development, and commercialization of innovative late-stage therapies targeting oncology. Beta Pharma specializes in personalized medicine by developing new chemical entity (NCE) drugs that target specific genetic mutations.[1]
History
In 1996, Beta Chemicals was founded in Science Park at Yale University as a contract research organization that provided custom synthesis to biotechnology and pharmaceutical companies. Two years later, it was renamed Beta Pharma, Inc. when the company started its first drug discovery project. Profits from the CRO business helped to fund the young company’s new drug discovery projects, which soon found success in oncology drugs.[2]
Product Pipeline
The first anti-cancer compound, icotinib, was identified and patented in 2003. A joint venture between Beta Chemicals and Zheijang Betta Pharmaceuticals Ltd, in China was formed and icotinib hydrochloride was licensed to Zheijang Betta Pharmaceuticals Ltd for further development. Currently, Beta Pharma, Inc. retains exclusive global rights to icotinib outside of China.
Beta Pharma was founded on identifying highly specific therapeutics to treat a variety of biomarker-driven cancers. They prioritize projects based on scientific understanding and clinical need and continue to make significant efforts to develop NCEs targeting advanced lung, breast, and pancreatic indications.
Locations
Beta Pharma, Inc. is developing a presence in the northeast region of the US; the corporate office is located in Princeton, NJ,[3] a research and development facility is located in Monmouth Junction, NJ, and a custom chemical synthesis laboratory in Branford, CT.[4]
Regulatory Activities
- June 2011, the SFDA approved icotinib hydrochloride for the treatment for non-small cell lung cancer in China.[5]
- January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).
References
- ↑ "Beta Pharma". Beta Pharma. Retrieved 9 September 2014.
- ↑ "Our History". Beta Pharma. Retrieved 9 September 2014.
- ↑ "Beta Pharma". Retrieved 20 August 2014.
- ↑ "Beta Pharma Inc". Retrieved 9 September 2014.
- ↑ Ruan, Can-Jun; Liu, Dong-Yang; Jiang, Ji; Hu, Pei (15 May 2012). "Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers". European Journal of Clinical Pharmacology. 68 (12): 1677–1680. doi:10.1007/s00228-012-1288-4.